Completed PHASE2 INTERVENTIONAL 2-arm NCT00757679

Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran

Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran. An Exploratory Placebo-controlled Clinical Trial in Fibromyalgia Out-patients

Sponsor: Pierre Fabre Medicament

Conditions Fibromyalgia Syndrome

Interventions Milnacipran Placebo

Updated 6 times since 2017 Last updated: Jul 10, 2013 Started: Sep 30, 2006 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00757679, this PHASE2 trial focuses on Fibromyalgia Syndrome and remains completed. Sponsored by Pierre Fabre Medicament, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pierre Fabre Medicament

Data source: Pierre Fabre Medicament

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland